Nature

A CLASP-modulated cell edge barrier mechanism drives cell-wide cortical microtubule organization in Arabidopsis

Plant tissues contain cells that are polyhedral in shape. The sharp edges marking the boundaries between adjacent cell faces present an interesting challenge to relatively rigid microtubules (MTs), ...
Business Wire

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

- CLSP-1025 targets the most common p53 mutation, a key oncogenic driver associated with multiple types of solid tumors, including gastrointestinal, lung, and gynecological cancers - Clasp's pHLAre™ ...
Business Wire

Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity

CAMBRIDGE, Mass. & ROCKVILLE, Md.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), ...
The Business Journals

Boston healthcare startup Clasp raises $20M to double staff, expand retention model

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company connects healthcare ...
C&EN

Clasp Therapeutics launches with $150 million in hand

Clasp Therapeutics, a company that aims to create a next-generation version of immunoncology drugs called bispecific T cell engagers (TCEs), launched today with $150 million in series A financing. The ...